Serina Therapeutics Files 8-K: Material Agreement & Equity Sales
Ticker: SER · Form: 8-K · Filed: Dec 2, 2024 · CIK: 1708599
| Field | Detail |
|---|---|
| Company | Serina Therapeutics, Inc. (SER) |
| Form Type | 8-K |
| Filed Date | Dec 2, 2024 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 5 min |
| Key Dollar Amounts | $0.0001, $10.00, $10 million, $18.00, $5 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, equity-sale, corporate-event
Related Tickers: SERN
TL;DR
Serina Therapeutics (SERN) filed an 8-K detailing a material agreement and equity sales. Keep an eye on this.
AI Summary
Serina Therapeutics, Inc. announced on November 26, 2024, that it entered into a Material Definitive Agreement. The company also reported on unregistered sales of equity securities and other events, including financial statements and exhibits. This filing follows a name change from AgeX Therapeutics, Inc. on June 6, 2017.
Why It Matters
This 8-K filing indicates significant corporate activity, including a new material agreement and equity transactions, which could impact the company's financial standing and future operations.
Risk Assessment
Risk Level: medium — Material definitive agreements and unregistered equity sales can introduce financial and operational risks, requiring careful monitoring.
Key Players & Entities
- Serina Therapeutics, Inc. (company) — Registrant
- November 26, 2024 (date) — Date of earliest event reported
- AgeX Therapeutics, Inc. (company) — Former company name
- June 6, 2017 (date) — Date of name change
FAQ
What is the nature of the Material Definitive Agreement Serina Therapeutics entered into?
The filing does not specify the details of the Material Definitive Agreement, only that one was entered into on November 26, 2024.
What type of equity securities were sold in the unregistered sales?
The filing mentions unregistered sales of equity securities but does not provide specific details about the type or amount of securities sold.
What are the key financial statements and exhibits included in this filing?
The filing indicates that financial statements and exhibits are included, but their specific content is not detailed in the provided text.
When did Serina Therapeutics change its name from AgeX Therapeutics, Inc.?
Serina Therapeutics, Inc. changed its name from AgeX Therapeutics, Inc. on June 6, 2017.
What is Serina Therapeutics' principal executive office address?
Serina Therapeutics' principal executive office is located at 601 Genome Way, Suite 2001, Huntsville, Alabama 35806.
Filing Stats: 1,176 words · 5 min read · ~4 pages · Grade level 14.2 · Accepted 2024-12-02 17:16:24
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share SER NYSE American Indic
- $10.00 — f Common Stock at the purchase price of $10.00 per share, for an aggregate amount of $
- $10 million — 0 per share, for an aggregate amount of $10 million in two tranches as described below, alo
- $18.00 — of Common Stock at an exercise price of $18.00 per share (the "Replacement Incentive W
- $5 million — res of Common Stock for an aggregate of $5 million occurred on November 27, 2024. In conne
Filing Documents
- form8-k.htm (8-K) — 48KB
- ex99-1.htm (EX-99.1) — 17KB
- ex99-1_001.jpg (GRAPHIC) — 5KB
- 0001493152-24-048316.txt ( ) — 256KB
- ser-20241126.xsd (EX-101.SCH) — 3KB
- ser-20241126_lab.xml (EX-101.LAB) — 34KB
- ser-20241126_pre.xml (EX-101.PRE) — 24KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SERINA THERAPEUTICS, INC. Date: December 2, 2024 By: /s/ Steve Ledger Chief Executive Officer